Depomed Inc

Depomed — Investor Day (March 2016)

143 slides from Depomed's investor day presentation, Mar 23, 2016

  1. Slide 1: Introduction

    Introduction Christopher Keenan Vice President, Investor Relations and Corporate Communications

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements March 2016 3 The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s strategy, plans, objectives, expectations (financial or ot

  3. Slide 3: Welcome and Overview

    Welcome and Overview Jim Schoeneck President and Chief Executive Officer

  4. Slide 4: Agenda and speakers

    March 2016 5 Introduction Chris Keenan Vice President, Investor Relations and Corporate Communications Welcome and Overview Jim Schoeneck President and Chief Executive Officer Pain: The Need for Change Joe Pergolizzi, Jr. M.D. Chief Operating Officer, Naples Anesthesia & Physician Associates Adjunct

  5. Slide 5: Our Mission

    Our Mission March 2016 6 Depomed is a growth – oriented, CNS-focused specialty pharmaceutical company that develops and commercializes innovative products that address unmet medical needs. Our unique products, capabilities and talented employees benefit the patients, families, physicians and other p

  6. Slide 6: Depomed Projected as Top #3 Branded Pain Company in US

    Depomed Projected as Top #3 Branded Pain Company in US by 2018 7 0 1 8 9 7 2 10 3 6 5 4 2016 2014 2018 2017 2015 US Net Sales ($Mil) 2013 2012 Depomed Horizon Pharma Teva Endo International Purdue Pharma Pfizer AbbVie Actavis Source: Decision Resources, March 2016 and Depomed analysis; Migraine sale

  7. Slide 7: Investment highlights

    Deliver Positive Cash Flow to De-Lever or Execute Acquisitions A Top Pain and Neurology Specialty Pharmaceutical Company Branded & Highly Differentiated Portfolio Lengthy Exclusivity Deals Track Record of Deals Demonstrate “Acquire, Integrate and Grow” Strategy Value Create Value through Organic Gro

  8. Slide 8: Depomed's Track Record of Successful Deals Builds Value

    Reworked Santarus deal and tripled net revenue 34% revenue growth Q4 2015 over Q4 2014 Acquired Q4 2013; relaunched Q1 2014; 26% revenue growth Q4 2015 over Q4 2014 Q3 2011 Non-strategic milestones & royalties sold for $240 million Relaunch Q4 2013 following acquisition; 154% revenue growth Q4 2015

  9. Slide 9: Driving Triple-Digit Growth in Sales and Significant Profitability

    10 $500K $27.1M $58.1M $114M $485M-$525M (1) 2016 Total Revenue Guidance Total product sales for 2016 are expected to be significant driven by NUCYNTA. There can be no assurance that the anticipated results will be achieved. Negative results for NUCYNTA may disproportionately impact Depomed $341M (I

  10. Slide 10: Significant Adjusted EBITDA Growth

    11 (1) 2012 and 2013 excludes divested diabetes portfolio (sold to PDL in 2013) (2) 2016 is midpoint of 2016 Adjusted EBITDA Guidance In millions of $ March 2016 Significant Adjusted EBITDA Growth $(64) $(38) $7 $111 $190 $(100) $(50) $- $50 $100 $150 $200 $250 2012 2013 2014 2015 2016 (1) (1) (2)

  11. Slide 11: Lengthy Exclusivity Periods

    Lengthy Exclusivity Periods 12 PRODUCT EXPECTED EXCLUSIVITY 2032+ Patents to 2032 Eligible for 5-year patent term extension 2028 3 primary patents, including composition of matter; ANDA suit pending 2024 Beat Actavis in U.S. District Court; Appeal – Settled in 2015 2024 4 Orange Book patents; patent

  12. Slide 12: Continue to Seek Opportunities in Pain, Neurology, and Adjacencies

    Continue to Seek Opportunities in Pain, Neurology, and Adjacencies 13 March 2016 PAIN NEUROLOGY ACQUIRE Pain and neurology products with lengthy exclusivity and peak sales ahead GROW Repositioning and marketing strategy drives unit demand and sales Acute nociceptive pain (Nucynta, Zipsor) Chronic no

  13. Slide 13: Depomed Positioned to Continue to Deliver Growth for Years

    Depomed Positioned to Continue to Deliver Growth for Years 14 March 2016 ORGANIC GROWTH Differentiated products with lengthy exclusivity Sustainable, unit growth EPS growth Leverage infrastructure NCEs NUCYNTA and Cebranopadol: potential game changers in pain INORGANIC GROWTH Acquisition of select l

  14. Slide 14: Pain: A Need for Change

    Pain: A Need for Change Joseph V. Pergolizzi, Jr, M.D. Johns Hopkins University and Temple University Schools of Medicine

  15. Slide 15: Joseph Pergolizzi, M.D. disclosures

    Joseph Pergolizzi, M.D. March 2016 16 DISCLOSURES: Dr. Pergolizzi is a consultant, lecturer and researcher for Depomed, CARA Therapeutics, Purdue Pharma, Grünenthal, Janssen, Horizon, Endo, Baxter, Iroko, TEVA, Astra Zeneca, Daiichi Sankyo, Salix, Shionogi, Scilex, Inspirion, Hikma, FDA, NIH, and a

  16. Slide 16: Pain: Time for Re-Evaluation

    March 2016 17 Pain: Time for Re-Evaluation

  17. Slide 17: Complex?

    Complex? 18 March 2016 pathophysiological PAIN visceral chronic neuropathic central malignant physiological nociceptive benign acute

  18. Slide 18: visceral

    visceral pathophysiological nociceptive chronic benign neuropathic acute central physiological malignant S0eromeD

  19. Slide 19: Einstein quote

    “You do not really understand something unless you can explain it to your grandmother.” Albert Einstein 1879 - 1955 March 2016 20

  20. Slide 20: Epidemiology of Pain

    Everyone experiences pain Chronic pain affects about 100 million American adults—more than the total affected by heart disease, cancer, and diabetes combined. Pain also costs the nation up to $700 billion Disproportionate amount of innovation exists Individualized manifestation requires need for sop

  21. Slide 21: Pain Classification

    Pain Classification Raffa, R, Tallarida ,R and Pergolizzi, J. Analgesic combinations. Submitted J. Pain June 2009. March 2016 22 PAIN CAN BE CLASSIFIED ACCORDING TO: Duration (e.g., acute pain, chronic pain) Site of origin (e.g., abdominal pain, leg pain) Cause (e.g., postoperative pain, tumor pain)

  22. Slide 22: Pain Market Overview

    Pain Market Overview 17% of all Patient Treatment Days (PTD) in pain are related to acute pain The remaining 83% of PTD divide into 52% Chronic nociceptive pain and 23% NP (Chronic defined as treatment duration >10 days) Pain with nociceptive and neuropathic component has a share on total chronic pa

  23. Slide 23: Most Pains are Multi-factorial

    Injury Peripheral Nerve Brain Descending Pathway Ascending Pathway Spinal Cord Dorsal Horn Dorsal Root Ganglion C-Fiber α-β Fiber α-δ Fiber Conduction Transduction Transmission/Modulation Perception Raffa R, Tallarida,R, Pergolizzi J. J Pain, 2010;11(8): 701-709. March 2016 24 Most Pains are Multi-f

  24. Slide 24: Chronic Pain is a 24-Hour Problem

    March 2016 25 Chronic Pain is a 24-Hour Problem Physical Functioning Interferes with normal daytime activities, walking and productivity2-4 May contribute to insomnia and sleep disturbance,2-6 which can also impair functioning2,3,5 42% to 88% of patients with chronic pain report poor sleep4,5 The re

  25. Slide 25: Overview of Pain Landscape and Current Challenges

    Pain is very personalized No “golden bullet” exists that works for everyone The impacts are enormous: In terms of QOL, cost, families, lives In adequately managed acute pain can lead to chronic pain 2016: A difficult time to be in pain in America It’s not easy treating pain either and it might be be

  26. Slide 26: The Need for Great Medicines

    Reason: Wrong substance? / Wrong Dose? Neuropathic pain component? Others? March 2016 27 The Need for Great Medicines PAIN PATIENT TREATMENT Sufficient treatment Insufficient analgesia Side-effects Still sufficient treatment Analgesic tolerance Struggles but stays Low Qol Inefficient Pain Management

  27. Slide 27: Pain Medicine as a Specialty is Young

    Emery Rovenstine (1895 – 1960) New York University “Events in the changing medical world have made it imperative that our functions be broadened and that we accept the challenge of pain occurring outside the surgical amphitheater. Such a concept fully justifies an anesthesia clinic on the therapy of

  28. Slide 28: Pain Modulation

    NEUROPATHIC PAIN COMPONENTS Caused by primary lesion or dysfunction in the nervous system2 Spinal stenosis Herniated disc with nerve root compression Radicular pain TINGLING3 STABBING3 BURNING3 1. Kozma CM et al. J Manag Care Spec Pharm. 2014;20(5):455-466b. 2. Morlion B. Curr Med Res Opin. 2011;27(

  29. Slide 29: Lack of knowledge in treating neuropathic pain

    Varrassi G, Müller-Schwefe G, Pergolizzi J , et al. Pharmacological treatment of chronic pain – the need for CHANGE. Current Medical Research and Opinion. 2010: 26(5): 1231-1245 There is a lack of knowledge and especially pain with a neuropathic component is difficult to treat 30 March 2016 There is

  30. Slide 30: Prescriptions for Pain Continue to Increase

    ER Opioids 25.8 million Rx IR Opioids 228.7 million Rx NSAIDs 89.8 million Rx Cox 2s 9.4 million Rx 354,000,000 Rx in the last year!!!! May 2012 to 2013 March 2016 31 Prescriptions for Pain Continue to Increase

  31. Slide 31: Choosing the Appropriate Medication

    ++ + + – + ± NOCICEPTIVE PAIN Visceral Soft tissue Bones Muscle spasm NEUROPATHIC PAIN Neural com- Pression Neural injury Opioid sensitivity Opioid + NSAIDs Muscle relaxants Opioid + cortico-steroids Opioids, tricyclic antidepressants / anticonvulsants, neuroleptics ... March 2016 32 Choosing the Ap

  32. Slide 32: Redefining the Step Ladder

    Patient #2 Patient #1 Patient #3 MODERATE SEVERE Non- Pharmacological Therapies Non- Pharmacological Therapies Pergolizzi and Raffa. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 4–6 Redefining the Step Ladder March 2016 33 Step 4 Step 3 Step 2 Step 1

  33. Slide 33: Tailoring Pain Therapy to Meet Individual Patient Needs

    AN INDIVIDUAL’S PAIN MAY MANIFEST AS ANY COMBINATION OF PAIN TYPE Osteoarthritis Chronic Anatomic Nociceptive Back pain Acute (or chronic) Anatomic Nociceptive or neuropathic Therapy should be chosen based on each patient’s personal and medical history Raffa R, and Pergolizzi J. JCT : 2013 March 201

  34. Slide 34: Why the Need for Opioids in Pain Armamentarium?

    De Vries F, et al.. Br J Clin Pharm. 2010;70(3):429-38. Solomon SD, et al. N Engl J Med. 2005;352(11):1071-80. Roumie CL, et al. 2008;39:2037-45. March 2016 35 Why the Need Opioids in Pain Armamentarium? GI Side effects Cardiovascular Side Effects Hepatic/Renal Toxicity NSAIDs1 COX-2 inhibitor2,3 Ac

  35. Slide 35: Unmet Medical Needs in Chronic Non Cancer Pain

    Unmet Medical Needs in Chronic Non Cancer Pain Many Patients Remain Inadequately Treated March 2016 36 Reduced pill burden Fast onset of action Longer duration of action Reduced awareness of pain; resume daily activities Improved efficacy and side effect profile Unmet needs in increasing level of im

  36. Slide 36: Drivers in Decision for an Analgesic

    TO BE ADDED: Individualisation Pre-Treatment Intensity of pain determining selection of drugs “Hassle factor” (prescription process) Cultural influence (patient opioiphobia) Co-morbidity Individual factors (e.g. age) Easy titration / dose adaptation March 2016 37 Cost Abuse potential Interactions wi

  37. Slide 37: Genetic Factors

    Genetic Factors Increasing recognition of genetic variations in humans in terms of: Expression of pain (eg Sodium channel pathologies) Response to analgesics (eg Cytochrome P450 slow or fast metabolisers; genetic mutations of opioid receptors and catecholamine metabolism) 38 Klepstad P. et al. The 1

  38. Slide 38: Abuse and Misuse of Prescription Drugs

    Abuse and Misuse of Prescription Drugs Centers for Disease Control and Prevention. Vital Signs: overdoses of prescription opioid pain relievers and other drugs among women in the United States, 1999–2010. MMWR. 2013;62:537-542. Murphy SL, Xu JQ, Kochanek KD. Deaths: Final data for 2010. National vit

  39. Slide 39: Opioid O.D. Deaths Crisis

    40 For every unintentional overdose death related to an opioid analgesic: 9 people admitted for substance abuse treatment 35 visit emergency departments 161 report drug abuse or dependence, and 461 report non-medical uses of opioid analgesics http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm Mar

  40. Slide 40: Opioid Induced Respiratory Depression

    Opioid Induced Respiratory Depression: OIRD OIRD is the chief hazardous concern with all opioids Over the last decade, opioid-related deaths in the US have increased at an alarming rate From 1999 to 2010, the rate of opioid overdose deaths increased 265% in men and 400% in women1 New York City resid

  41. Slide 41: CDC Opioid Prescribing Guidelines

    https://events-na12.adobeconnect.com/content/connect/c1/1278955669/en/events/event/shared/default_template/event_landing.html?sco-id=1392440305 March 2016 CDC: Engaging Providers, Patients, and Organizations on Draft CDC Opioid Prescribing Guidelines for Chronic Pain 42

  42. Slide 42: CMS: Opioid Overutilization Guidelines

    CMS: Opioid Overutilization Guidelines https://www.cms.gov/Medicare/Prescription-Drug-coverage/PrescriptionDrugCovContra/RxUtilization.html March 2016 43

  43. Slide 43: VA Opioid Safe Initiative

    VA Opioid Safe Initiative http://www.va.gov/opa/pressrel/pressrelease.cfm?id=2529 March 2016 44

  44. Slide 44: ONDCP's Prescription Drug Abuse Prevention Plan

    The 2011 Prescription Drug Abuse Prevention Plan expands upon the Obama Administration's National Drug Control Strategy and includes action in four major areas to reduce prescription drug abuse: March 2016 45 ONDCP's Prescription Drug Abuse Prevention Plan Education Monitoring Proper medication disp

  45. Slide 45: FDA Abuse-Deterrent Opioid Guidance Provides a Path

    http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf March 2016 46 The FDA Abuse-Deterrent Opioid Guidance Provides a Path For Drug Developers

  46. Slide 46: Abuse-Deterrent Properties

    Abuse-Deterrent Properties FDA Draft Guidance “Abuse-Deterrent Opioids –Evaluating and Labeling” September 2015 March 2016 47 “This guidance is intended to assist sponsors who wish to develop formulations of opioid drug products with potentially abuse-deterrent properties (abuse-deterrent formulatio

  47. Slide 47: Undertreatment of chronic pain

    Richard J, Reidenberg MM. J Pain Symptom Manag. 2005;29:206-212. Gilson AM et al. J Pain. 2007;8:682-691. Jung B, Reidenberg MM. Pain Med. 2006;7:353-357. McCracken LM et al. J Pain. 2006;7:726-734. Primm BJ et al. J Natl Med Assoc. 2004;96:1152-1161. Socioeconomic and psychological factors6,7,10 Go

  48. Slide 48: Situational Analysis

    March 2016 49 Situational Analysis We have a crippling disease, but we are still using old medicines. Other specialties have access to numerous novel innovations. We need options that address the complexity of pain in a multi-mechanistic manner. With the right arsenal and proper education we can def

  49. Slide 49: We REALLY Need a Better Mousetrap

    We REALLY Need a Better Mousetrap 50 March 2016

  50. Slide 50: We REALLY Need a Better Mousetrap

    We REALLY Need a Better Mousetrap 3 3DEPOMED

  51. Slide 51: Tapentadol: A CII Opioid for the 21st Century

    Tapentadol: A CII Opioid for the 21st Century Morphine commercialized In 1827 March 2016 52

  52. Slide 52: Tapentadol's Unique Pharmacology

    Tapentadol’s Unique Pharmacology Increasing norepinephrine transporter affinity Increasing μ-opioid receptor affinity Tapentadol (NUCYNTA) March 2016 53 Duloxetine (Cymbalta™) Oxycodone (Oxycontin™)

  53. Slide 53: Resulting in a Broad Analgesic Spectrum

    Resulting in a Broad Analgesic Spectrum March 2016 54 Increasing Efficacy in Neuropathic Pain Increasing Efficacy in Nociceptive Pain Duloxetine (Cymbalta™) Oxycodone (Oxycontin™) Tapentadol (NUCYNTA)

  54. Slide 54: Improved Safety vs. Traditional Opioids

    Oxycodone (Oxycontin™) And Improved Safety vs. Traditional Opioids March 2016 55 Increasing Respiratory Depression Increasing Abuse Potential Duloxetine (Cymbalta™) Tapentadol (NUCYNTA)

  55. Slide 55: Tapentadol Abuse Potential: Post Marketing Evaluation

    Pain Medicine Volume 16, Issue 1, pages 119-130, 22 SEP 2014 DOI: 10.1111/pme.12524 http://onlinelibrary.wiley.com/doi/10.1111/pme.12524/full#pme12524-fig-0001 Tapentadol Abuse Potential: A Post Marketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment March 2016 56

  56. Slide 56: Rate of Diversion of Tapentadol vs other CII Opioids

    Rate of Diversion of Tapentadol IR and ER versus other CII Opioid Tablets July 1, 2009 - September 30, 2014 Rate of diversion of Tap versus other CII Dates Richard C. Dart et al. Pain Med 2015;pm.pnv032 March 2016 57

  57. Slide 57: Median Street Price of Tapentadol and other CII Opioids

    Median Street Price of Tapentadol IR and ER, and other CII Opioid Tablets, January 1, 2011 - September 30, 2014 Richard C. Dart et al. Pain Med 2015;pm.pnv032 March 2016 58

  58. Slide 58: Time to re-evaluate approach to chronic pain

    It is time to re-evaluate our approach to the treatment and management of chronic pain. Change Pain Group 2009 March 2016 59

  59. Slide 59: Commercial Update

    Commercial Update Scott Shively Chief Commercial Officer

  60. Slide 60: Key Points

    Pain and Neurology A Large and Growing Opportunity Depomed Brands Highly Differentiated and Strongly Positioned NUCYNTA Building Our Flagship Franchise Depomed Demonstrated Ability to Rapidly Transition, Relaunch and Accelerate Growth March 2016 61 Key Points

  61. Slide 61: Pain and Neurology is a Large Segment of US Pharmaceutical Market

    Sources: Depomed analyses, Decision Resources Market Analyzer 15.1% 13.3% 10.7% 9.5% 9.3% 8.4% 8.0% 5.9% 4.4% 4.1% 3.0% 3.0% 2.9% 2.6% March 2016 62 Pain and Neurology is a Large Segment of the $340 Billion U.S Pharmaceutical Market in 2015 Pain/Neurology is the Second Largest Segment of US Pharmace

  62. Slide 62: Total Sales of Branded Pain Market Segments

    500 1,500 2,500 4,000 3,000 1,000 2,000 0 4,500 3,500 Gross sales, 2015 (US; $Mil) 326 Muscle relaxants Anti-depressants (for pain) 420 TIRFs 2,581 4,392 Opioids* 4,161 NSAIDS 1,531 Other pain Anesthetics *Opioids market includes injectables; excludes TIRF. TIRF = Transmucosal Immediate Release Fent

  63. Slide 63: Patient types across pain conditions

    64 March 2016 ACUTE PAIN CLBP DPN MIGRAINE PHN BREAKTHROUGH PAIN Weekend Warrior: Active Adult who needs rapid and effective relief for mild to moderate acute pain Serious Injury/Surgery: Moderate to severe acute pain for several days, taking time off work due to severity of pain Middle-Aged Worker:

  64. Slide 64: NUCYNTA Franchise

    NUCYNTA Franchise March 2016 65

  65. Slide 65: NUCYNTA ER: Year-Over-Year Rx Growth

    Source: Monthly IDV (Retail and Mail Order) Depomed launch March 2016 66 NUCYNTA ER: Year-Over-Year Rx Growth Now 22.1% up from 1.3% in 9 Months Linear 0.0% 4.0% 8.0% 12.0% 16.0% 20.0% May-2015 Jun-2015 Jul-2015 Aug-2015 Sep-2015 Oct-2015 Nov-2015 Dec-2015 Jan-2016 Feb-2016 NUCYNTA ER Monthly TRx Y

  66. Slide 66: NUCYNTA: Volume Trends Growing Positive

    Depomed launch March 2016 67 NUCYNTA: Volume Trends Growing Positive in Recent Months Source: Monthly IDV (Retail and Mail Order) -12.0% -10.0% -8.0% -6.0% -4.0% -2.0% 0.0% 2.0% May-2015 Jun-2015 Jul-2015 Aug-2015 Sep-2015 Oct-2015 Nov-2015 Dec-2015 Jan-2016 Feb-2016 NUCYNTA Monthly TRx Y - o - Y Vo

  67. Slide 67: Key Issues/Opportunities and Launch Strategies

    Key Issues/Opportunities Launch Strategies Inconsistent/insufficient sales force execution by J&J Increased sales force to 301 reps, with NUCYNTA/NUCYNTA ER as #1 priority Perception of poor efficacy Re-positioned NUCYNTA franchise for patients with combination of nociceptive and neuropathic pain ba

  68. Slide 68: NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion

    (1) There can be no assurance that the anticipated results will be achieved March 2016 Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales1 69 Promotion Significantly increased promotion and marketing efforts 1 Positioning Revamped product positioning and messaging 2 Pricing

  69. Slide 69: Significantly Increased Promotion and Marketing Efforts

    Promotion 1 In 2015, increased salesforce to 277 promoting NUCYNTA (vs 80 with Janssen), in February 2016 added 24 Lazada reps 25,000 targets in Call-plan (vs 7000 with Janssen CSO) Innovative segmentation approach to target highest potential prescribers Executed over 300,000 NUCYNTA ER details sinc

  70. Slide 70: Revamped NUCYNTA and NUCYNTA ER Positioning

    March 2016 Revamped NUCYNTA AND NUCYNTA ER Positioning 71 Positioning 2 The first unique molecule of the centrally acting analgesic class approved since 1984 A µ-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI) Powerful efficacy in various pain models Well defined tolerabi

  71. Slide 71: Tapentadol: Designed as a Next-Generation Long-Acting Opioid

    Tapentadol is a centrally acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a µ-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is

  72. Slide 72: NUCYNTA MOA Video

    NUCYNTA MOA Video March 2016 73

  73. Slide 73: Marketing Collateral Brings Patient Profiles to Life

    cLBP Patient Profile DPN Patient Profile Acute /cLBP Patient Profile Acute Pain Patient Profile March 2016 74 Marketing Collateral Brings Patient Profiles to Life

  74. Slide 74: NUCYNTA ER's Efficacy Attribute Significantly Improved Since Re-launch

    Total* (n=171,121) Unaided NUCYNTA ER Awareness in Chronic Pain (n=172, 167) Proven efficacy in established chronic pain with nociceptive and neuropathic components (ie cLBP) Efficacy in a broad range of pain conditions, including low back, and neuropathic A low incidence of side effects/overall tol

  75. Slide 75: Class-Leading Commercial Access

    March 2016 Class-Leading Commercial Access 76 Pricing and Access 3 76% of commercial patients have unrestricted access to NUCYNTA ER versus OxyContin (76%) and Opana ER (68%) Cigna – NUCYNTA and NUCYNTA ER are both in a Tier 2 position (January) Blue Cross Blue Shield Tennessee - has NUCYNTA and NUC

  76. Slide 76: Educating Physicians on Titration

    March 2016 Educating Physicians on Titration 77 Proper Dosing 4 Lower back pain study – ~400mg/day average dose after titration Marketplace – ~258 mg/ day average dose after titration1 Appropriate conversation on titration a part of every sales presentation Efficacy perception is improving markedly

  77. Slide 77: Experienced Senior Commercial Leadership and Marketing Team

    Experienced Senior Commercial Leadership and Marketing Team Concentrated experience within Pain and Neurology sectors Experience: Pfizer, Lilly, Purdue, Alpharma, Mallinckrodt, Endo, Hoechst Marion Roussel, Sanofi-Aventis, Ortho-McNeil, Baxter, GSK, Zogenix Salesforce Overview Average 15 years sales

  78. Slide 78: Portfolio Products

    Portfolio Products March 2016 79

  79. Slide 79: Gralise

    March 2016 80 Reacquired marketing rights March 2011 and received $40M payment 34% increase Y-o-Y revenues >$86 million run rate as of Q4 2015 Management of postherpetic neuralgia Once daily, less dizziness and somnolence Night and day Growth Potential: Increase neurology utilization and capture swi

  80. Slide 80: Cambia

    March 2016 81 Cambia® Acquired in December 2013 for $48.7M 26% increase Y-o-Y revenues >$32 million run rate as of Q4 2015 Acute migraine attacks in adults Only single-agent in therapeutic class for acute migraine Growth Potential: Differentiate based on rapid onset of action and relief

  81. Slide 81: Lazanda

    March 2016 82 Lazanda® Acquired in July 2013 for $4M 154% increase Y-o-Y revenues $21 million run rate as of Q4 2015 Breakthrough cancer pain Only nasally-delivered fentanyl product Growth Potential: Differentiate nasal delivery advantages, show preferred treatment for patients with oral complicatio

  82. Slide 82: Summary

    March 2016 83 Summary Experienced Pain Team with Demonstrated Ability to Execute and Drive Growth Highly Differentiated Product Portfolio – Six Brands with Lengthy Exclusivity NUCYNTA ER TRxs Growing 20%+ YOY and Accelerating. NUCYNTA Starting to Grow New NUCYNTA ER Positioning and Messaging Changin

  83. Slide 83: Question and Answer Session

    Question and Answer Session

  84. Slide 84: Cebranopadol: A Potent Analgesic with Novel Pharmacology

    CEBRANOPADOL A Potent Analgesic with Novel Pharmacology: NOP and Opioid Receptor Agonism Srini Rao, M.D., Ph.D. Chief Medical Officer

  85. Slide 85: Why Cebranopadol?

    Why Cebranopadol? First of a new class of analgesics Opioid-like efficacy in musculoskeletal pain Efficacy in neuropathic pain Better safety vs. typical opioids: reduced abuse potential and respiratory depression March 2016 86

  86. Slide 86: Cebranopadol Overview

    Cebranopadol Overview First-in-class pharmacology: NOP receptor agonist Opioid agonist Orally administered with pharmacokinetics that support once-a-day dosing Phase III Ready March 2016 87

  87. Slide 87: NOP Receptor: A Novel Analgesic Target

    “Nociceptin/Orphanin FQ peptide” (NOP) receptor discovered in 1994 NOP is in the same receptor family as the μ, κ, and opioid receptors, though with distinct pharmacology Highly expressed in brain regions associated with both pain perception and drug abuse. NOP Receptor: A Novel Analgesic Target Mar

  88. Slide 88: Cebranopadol's Unique Pharmacology

    Compound NRI NOP agonist μ-opioid agonist κ-opioid agonist -opioid agonist κ-opioid antagonist -opioid antagonist Cebranopadol Tapentadol Morphine, Oxycodone, Hydrocodone, Oxymorphone, Hydromorphone, Fentanyl Buprenorphine* Mechanism(s)-of-Action *CIII drug substance March 2016 89 Cebranopadol’s Uni

  89. Slide 89: Cebranopadol: Pharmacological Synergy

    μ-opioid Receptor Activation Effective against nociceptive pain But: Visceral & neuropathic pain are relatively opioid resistant Respiratory depression Addiction risk Potent and broad analgesic activity in pain with reduced risk of respiratory depression and addiction risk vs. “traditional” opioids

  90. Slide 90: Why Cebranopadol?

    Why Cebranopadol? First of a new class of analgesics Opioid-like efficacy in musculoskeletal pain Efficacy in neuropathic pain Better safety vs. typical opioids: reduced abuse potential and respiratory depression March 2016 91

  91. Slide 91: Overview of Completed Clinical Studies

    Over 2000 individuals exposed to cebranopadol to date 7 Phase II trials completed Broad dose range explored 25 – 1600 µg/ day Overview of Completed Clinical Studies March 2016 92

  92. Slide 92: Phase II Clinical Trial Summary

    March 2016 93 Phase/ Trial # Pts Trial Design Cebranopadol Doses (µg) Comparators & Dose (mg) Chronic Lower Back Pain (cLBP) IIb “06” 635 12-week 5 Parallel Arms Tapentadol 400mg Placebo Painful Diabetic Peripheral Neuropathy (DPN) IIb “08” 314 6-week 4 Parallel Arms Pregabalin 600mg Placebo IIa “04

  93. Slide 93: Phase II Results: Positive Trials

    Phase II Results: 5 Positive Trials Phase # Pts Trial Arms (ALL include placebo) Results Chronic Lower Back Pain (cLBP) IIb 635 Cebranopadol: 200,400, 600 µg Tapentadol: 400 mg Statistically significant results for tapentadol and all doses of cebranopadol vs. placebo Painful Diabetic Peripheral Neur

  94. Slide 94: cLBP: Phase IIb Trial Design

    cLBP: Phase IIb Trial Design Treatment Period 635 Patients Randomized Aggressive cebranopadol titration: Initiation at 200 µg Dose escalation every 3 days Dose increment of 200 µg March 2016 95 Maintenance Phase 12 weeks Titration Phase 14 days Tapentadol Twice Daily 200 mg 50-100-150-200 mg Cebrano

  95. Slide 95: cLBP: Robust Efficacy Across All Dosages

    from Baseline Trial Week Titration Maintainence Weekly Average 24h Pain Scores from Baseline P – Values 200mcg: 0.0095 400mcg: 0.0122 600mcg: 0.0021 March 2016 96 cLBP: Robust Efficacy Across All Dosages

  96. Slide 96: cLBP: Tolerability, Titration vs. Maintenance

    cLBP: Tolerability, Titration vs. Maintenance Dizziness Nausea Vomiting Fatigue Placebo N=126 Cebranopadol 200 µg N=131 Cebranopadol 400 µg N=128 Cebranopadol 600 µg N=130 Tapentadol 400 mg N=126 Discontinuation due to AE 3.2% 32.1% 40.6% 47.7% 26.2% a) Titration period 25% 41% 54% 73% 42% b) Mainte

  97. Slide 97: DPN Pain: Phase IIb Trial Design

    DPN Pain: Phase IIb Trial Design Treatment Period 314 Patients Randomized Aggressive cebranopadol titration for 300 & 600 µg arms: Initiation at 200 µg (600µg arm) Dose escalation every 3 days Dose increment of 200 µg March 2016 98 Maintenance Phase 6 weeks Titration Phase 14 days Pregabalin Twice D

  98. Slide 98: DPN: Statistical Separation at 600 µg Dosage

    from Baseline Trial Week Weekly Average 24h Pain Scores from Baseline March 2016 99 DPN: Statistical Separation at 600 µg Dosage P – Values 100mcg: 0.0621 300mcg: 0.0564 600mcg: 0.0153

  99. Slide 99: DPN: Tolerability, Titration vs. Maintenance

    Placebo N=63 Cebranopadol 100 µg N=64 Cebranopadol 300 µg N=61 Cebranopadol 600 µg N=63 Pregabalin 600 mg N=65 Discontinuation due to AE 7.9% 12.5% 27.9% 47.6% 12.3% a) Titration period 60% 50% 53% 73% 25% b) Maintenance period 40% 50% 47% 27% 75% DPN: Tolerability, Titration vs. Maintenance March 2

  100. Slide 100: Why Cebranopadol?

    Why Cebranopadol? First of a new class of analgesics Opioid-like efficacy in musculoskeletal pain Efficacy in neuropathic pain Better safety vs. opioids: reduced respiratory depression and reduced abuse potential March 2016 101

  101. Slide 101: Respiratory Function Study

    Oral cebranopadol (600 µg) vs. IV fentanyl (3.5 µg/kg) Outcome of interest: respiratory rate March 2016 102 Respiratory Function Study Treatment Period Period 1 Washout Period 2 Cebranopadol Fentanyl Fentanyl Cebranopadol 12 Subjects Randomized Acute, crossover trial to evaluate the effect of cebran

  102. Slide 102: Cebranopadol: Limited Impact on Respiratory Rate

    March 2016 103 Cebranopadol: Limited Impact on Respiratory Rate Mean Respiratory Rate [Breaths/min] Time [h] 0 2 4 6 8 10 12 8 10 12 14 16 19 Treatment: Fentanyl IV Cebranopadol 600 µg

  103. Slide 103: Human Abuse Liability (HAL) Study

    Human Abuse Liability (HAL) Study March 2016 104 Design: 7-way, crossover trial with pre-enrichment in non-dependent recreational opioid users Objective: To evaluate the abuse potential of cebranopadol relative to hydromorphone (HMO) IR and placebo Non-dependent recreational opioid users (m/f) No si

  104. Slide 104: Cebranopadol: Reduced Abuse Potential

    Cebranopadol: Reduced Abuse Potential Results: Therapeutic doses: cebranopadol’s likability similar to placebo Supratherapeutic dose: Maximum likability occurs 5h after dosing Moreover: Cebranopadol administered intranasally showed similar PK as oral administration in non-human primates Cebranopadol

  105. Slide 105: Summary

    Summary Effective across both nociceptive and neuropathic pain states when dosed once daily –Efficacy has been established to 14 weeks of therapy –Dose-response relationship has been established Respiratory depression is of limited magnitude “Human Abuse Potential” trial results support lower schedu

  106. Slide 106: Overview of Clinical Development Plan

    Overview of Clinical Development Plan

  107. Slide 107: 2014 FDA Draft Guidance on Analgesics Development

    2014 FDA Draft Guidance on Analgesics Development* *Guidance for Industry Analgesic Indications: Developing Drug and Biological Products”, U.S. Department of Health and Human Services FDA/CDER, February 2014 March 2016 108 Chronic Musculoskeletal Pain Single Indication Label 2 trials in single indic

  108. Slide 108: Development Plan to cLBP & Beyond

    Development Plan to cLBP & Beyond March 2016 109 2 Phase III Trials In Chronic Low Back Pain “Chronic low back pain severe enough to require...opioid therapy” 1 Phase III Trial In Knee OA “Chronic musculoskeletal pain severe enough to require... opioid therapy”

  109. Slide 109: Optimizing Dose Titration

    Optimizing Dose Titration Analysis of dosages and titration schemes across all Phase II studies completed, with a focus on AE’s resulting in discontinuations Simulation suggests a >40% reduction in dropouts with this titration regimen March 2016 110

  110. Slide 110: Summary

    Summary March 2016 111 \ Cebranopadol’s demonstrated properties: Opioid-like efficacy in nociceptive pain Efficacy in neuropathic pain (unlike typical opioids) Limited respiratory depression Low likability vs. typical opioid The next stage of evolution in innovative, multi-mechanistic analgesic ther

  111. Slide 111: Cebranopadol: The Next Frontier

    Cebranopadol: The Next Frontier Joseph V. Pergolizzi, Jr, MD Johns Hopkins University and Temple University Schools of Medicine

  112. Slide 112: Cebranopadol

    Cebranopadol Joseph V. Pergolizzi, Jr, MD Johns Hopkins University and Temple University Schools of Medicine

  113. Slide 113: Value Proposition for Addressing Current Unmet Needs in CNCP

    Value Proposition for Addressing Current Unmet Needs in CNCP March 2016 114 Cebranopadol Clinical Data: Thoughts Cebranopadol: Potential Market Differentiation Cebranopadol: Changing the Pain Landscape Treatment Discussion The Pain Specialist: Need for Novel Treatment Modalities

  114. Slide 114: Could Cebranopadol be a Good Option in Chronic Musculoskeletal and DPN Pain?

    March 2016 115 Could Cebranopadol be a Good Option in Chronic Musculoskeletal and DPN Pain Management? Novel mechanism-of-action –NOP receptor agonist –Pan opioid effect: Agonist at μ-and κ-opioid receptors Initial data shows reliable safety and efficacy for pain in various types of chronic non-canc

  115. Slide 115: Complex?

    Complex? 116 March 2016 pathophysiological PAIN visceral chronic neuropathic central malignant physiological nociceptive benign acute

  116. Slide 116: Lack of Knowledge; Neuropathic Pain Difficult to Treat

    Varrassi G, Müller-Schwefe G, Pergolizzi J , et al. Pharmacological treatment of chronic pain – the need for CHANGE. Current Medical Research and Opinion. 2010: 26(5): 1231-1245 There is a Lack of Knowledge and Especially Pain with a Neuropathic Component is Difficult to Treat March 2016 There is li

  117. Slide 117: Drivers in Decision for an Analgesic

    TO BE ADDED: Individualisation Pre-Treatment Intensity of pain determining selection of drugs “Hassle factor” (prescription process) Cultural influence (patient opioiphobia) Co-morbidity Individual factors (e.g. age) Easy titration / dose adaptation March 2016 118 Cost Abuse potential Interactions w

  118. Slide 118: Pain therapy classes

    119 March 2016 Tylenol NSAIDS Local Anesthetics Opiates Weak Opiates Opioid Combinations Analgesics Ketamine Gabepentin

  119. Slide 119: Analgesia and the Pain Pathway

    Dorsal horn Local anesthetics Opioids 2-agonists COX-2 selective inhibitors NSAIDs=nonsteroidal anti-inflammatory drugs. Descending modulation Ascending input Spinothalamic tract Dorsal root ganglion Peripheral nerve Peripheral nociceptors 120 March 2016 Analgesia and the Pain Pathway PAIN Adapted f

  120. Slide 120: Drug Combinations: Expected Outcome

    Analgesia AE Combination OK Best OK No benefit if analgesia, AE , or both Drug Combinations: Expected Outcome 121 March 2016

  121. Slide 121: Loose Drug Combinations

    Combining different analgesic principles may lead to additive effects for analgesia and side effects Hanna et al. 2008, Gilron et al. 2005 Loose Drug Combinations March 2016 Loose drug combinations carry the risk of: Drug–drug interactions Non-complementary pharmacokinetic profiles Related side-effe

  122. Slide 122: Chronic Low Back Pain May Include Both Nociceptive and Neuropathic Components

    NEUROPATHIC PAIN COMPONENTS Caused by primary lesion or dysfunction in the nervous system2 Spinal stenosis Herniated disc with nerve root compression Radicular pain TINGLING3 STABBING3 BURNING3 1. Kozma CM et al. J Manag Care Spec Pharm. 2014;20(5):455-466b. 2. Morlion B. Curr Med Res Opin. 2011;27(

  123. Slide 123: Mechanism-Based Pain Diagnosis

    Ideal for pain management is to measure symptoms and to treat pain mechanisms Woolf CJ, Mannion RJ. Lancet. 1999;353:1959-64. Woolf, C. J. ,Max MB. Anesthesiology. 2001; 95: 241-249. March 2016 124 Mechanism-Based Pain Diagnosis Disease/Injury Mechanism Signs/Symptoms Treat Measure Syndrome Identifi

  124. Slide 124: Treatment of Pain with Multiple Underlying Mechanisms

    Treatment of Pain with Multiple Underlying Mechanisms Combination therapy or higher doses often result in decreased tolerability Tapentadol is currently the only single entity central acting multi-mechanistic analgesic that effectively addresses both neuropathic and nociceptive components Cebranopan

  125. Slide 125: Key Opiate Risks

    Key Opiate Risks to Assist in Addressing Opioid Concerns March 2016 126 Drug abuse 1 Physical dependence 2 Psychological dependence 3 Overdose 4 Respiratory depression 5

  126. Slide 126: Multi-mechanistic Analgesia Cebranopadol: One Key for Multiple Locks

    Multi-mechanistic Analgesia Cebranopadol: One Key for Multiple Locks 127 March 2016

  127. Slide 127: Cebranopadol – Uniquely Designed to Address Unmet Needs

    Order of Importance March 2016 128 Cebranopadol – Uniquely Designed to Address Unmet Needs of Chronic Non Cancer Pain Management Benefits of Cebranopadol’s: Opioid-like efficacy in nociceptive pain and efficacy in neuropathic pain (unlike typical opioids) Stable pain management improved tolerability

  128. Slide 128: Could Cebranopadol be a Good Option in Chronic Musculoskeletal and DPN Pain?

    129 March 2016 Could Cebranopadol be a Good Option in Chronic Musculoskeletal and DPN Pain Management? Novel mechanism-of-action –NOP receptor agonist –Pan opioid effect: Agonist at μ-and κ-opioid receptors Initial data shows reliable safety & efficacy for pain in various types of chronic non-cancer

  129. Slide 129: Oliver Wendell Holmes quote

    “Greatness is not in where we stand, but in what direction we are moving.” Oliver Wendell Holmes March 2016 130

  130. Slide 130: Oliver Wendell Holmes quote

    “Greatness is not in where we stand, but.in what direction we are moving.” Oliver Wendell Holmes Se0eromeD

  131. Slide 131: Financial Overview

    Financial Overview August Moretti Chief Financial Officer

  132. Slide 132: Strong 2015 Financial Performance

    Strong 2015 Financial Performance March 2016 133 2015 Net Product Sales $342 million Full Year Non-GAAP Adjusted EBITDA $111 million Cash Generated Post NUCYNTA $167 million Cash at 12/31/15 $210 million Includes 9 Months of NUCYNTA Sales

  133. Slide 133: 2016 Guidance Reflects Robust Net Sales Growth

    2016 Guidance Reflects Robust Net Sales Growth March 2016 134 Total Revenue $485 to $525 million Total Non-GAAP SG&A Expense $180 to $195 million Total Non-GAAP R&D Expense $30 to $40 million Non-GAAP Adjusted Earnings $95 to $115 million Non-GAAP Adjusted EBITDA $175 to $205 million The Company exp

  134. Slide 134: Cebranopadol is a Potential Game Changer

    Cebranopadol is a Potential Game Changer Development Expense Through Phase 3 of Approximately $100M March 2016 135 2016 Eligible for R&D Tax Credits Front-end loaded ~$10M 2017-2019 ~$90M

  135. Slide 135: Strong Cash Flow Enables Rapid Deleveraging

    Strong Cash Flow Enables Rapid Deleveraging Strong Cash Flow: Generated $167M in cash in 9 months since NUCYNTA re-launch $575M of Secured Debt and $210M cash at 12/31/15 April 4, 2016: Will prepay $100M of principal of Secured Debt April 2017: Expect to either: further prepay to reduce the outstand

  136. Slide 136: Strong Cash Flow Enables Rapid Deleveraging

    Strong Cash Flow Enables Rapid Deleveragin » Strong Cash Flow: Generated $167M in cash in 9 months since NUCYNTA re-launch * $575M of Secured Debt and $210M cash at 12/31/15 + April 4, 2016: Will prepay $100M of principal of Secured Debt ~ Api 2017: Expect to ether: Passi 016 | or 2017 | further pre

  137. Slide 137: Question and Answer Session

    Question and Answer Session > >\KDEPOMED

  138. Slide 138: James A. Schoeneck

    James A. Schoeneck March 2016 139 James A. Schoeneck, President and Chief Executive Officer Mr. Schoeneck joined Depomed as president and chief executive officer in April 2011 and has served on the company’s Board of Directors since December 2007. From 2005 until joining Depomed, Mr. Schoeneck was c

  139. Slide 139: August J. Moretti

    August J. Moretti March 2016 140 August J. Moretti, Senior Vice President and Chief Financial Officer Mr. Moretti joined Depomed as senior vice president and chief financial officer in January 2012. From 2004 to December 2011 he was chief financial officer and senior vice president of Alexza Pharmac

  140. Slide 140: R. Scott Shively

    R. Scott Shively March 2016 141 R. Scott Shively, Chief Commercial Officer Mr. Shively joined Depomed as chief commercial officer in August 2014 bringing with him extensive commercial leadership experience in sales and marketing of pain and neurology products, for both specialty as well as larger ph

  141. Slide 141: Srinivas G. Rao, M.D., Ph.D

    SrinivasG. Rao, M.D., Ph.D 142 March 2016 SrinivasG. Rao, M.D., Ph.D, Chief Medical Officer Dr. Rao joined Depomed as chief medical officer in July, 2014. He brings with him extensive experience and background in pain and central nervous system diseases. He was the founder and chief executive office

  142. Slide 142: Joseph V. Pergolizzi, Jr., M.D.

    Joseph V. Pergolizzi, Jr., M.D. March 2016 143 Joseph V. Pergolizzi, Jr., M.D. Dr. Pergolizzi is Chief Operating Officer, Naples Anesthesia & Physician Associates and an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine. Dr. Pergolizzi is a form

  143. Slide 143: Joseph V. Pergolizzi, Jr., M.D.

    Joseph V. Pergolizzi, Jr., M.D Joseph V. Pergolizzi, Jr., M.D. Dr. Pergolizzi is Chief Operating Officer, Naples Anesthesia & Physician Associates and an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine. Dr. Pergolizzi is a former Adjunct Facul

Depomed — Investor Day (March 2016) on 6ix